future of glp-1 drugs Costs Explained: Managing Coverage Challenges GLP-1 Antagonists Increase Plan Drug

Emerging oral and long-acting formulations may overcome barriers to self-injection in frail or cognitively impaired populations

Jebb and colleagues are among the first to trace this trajectory

[DOI] [Google Scholar] 30.Bettge K., Kahle M., Abd El Aziz M.S., Meier J.J., Nauck M.A

R.HolscherC.GaultV

76,81,96,97 The main factor contributing to the lack of greater investment in lixisenatide and other short-acting agents for MASLD may be their influence on metabolic function, including pharmacokinetic differences induced by a single-dose method and their effects on gastric emptying, 91 which could limit their effectiveness in improving glycolipid metabolism

Another potential advantage of this combination is mitigation of insulin-associated weight gain when used in combination with a GLP-1 RA